Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2006

View Archived Issues

AEterna Zentaris presents pipeline round-up

Orphan drug designation for Valortim in treatment of anthrax infection

Phase III efficacy trials begin for Technosphere Insulin

Priority review for TMC-114

Infinity and Novartis collaborate on Bcl-2 family inhibitors

Nereus closes second tranche of financing

Velcade studied in combination with pemetrexed for advanced NSCLC

Enrollment completed in phase I study of Chemophase for bladder cancer

Endovasc submits phase IIIa Liprostin protocol to FDA

Positive results for CX-717 in adults with ADHD

Positive Advisory Committee vote for Cubicin sNDA

Anti-rabies monoclonal antibody combination effective in vitro and in vivo

Mometasone nasal spray reduces nasal polyps

Intraperitoneal chemotherapy beneficial in patients with ovarian cancer

Safety, pharmacokinetics and comparative efficacy of BAY-59-7939 evaluated

LS-104 targets mutated Flt3 to provide enhanced anti-AML activity

Novel agents for nephritis disclosed in recent Shionogi patent

Xyrem launched for excessive daytime sleepiness in narcolepsy patients

Dasatinib NDA accepted for priority review

Recent patents cover therapeutic agents for neurological disorders

Novel antidiabetic agents disclosed in recent patents

S-236 cream may be used to promote barrier repair in atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...